Related Experiment Video
Updated: Jun 17, 2026
05:44
Rodent Inferior Vena Cava Venoplasty Balloon Model
Published on: May 24, 2024
Emerging drugs for venous thromboembolism
Gualtiero Palareti1, Benilde Cosmi
1University Hospital S. Orsola-Malpighi, Department of Angiology and Blood Coagulation Marino Golinelli, Via Albertoni 15, 40138 Bologna, Italy. gualtiero.palareti@unibo.it
Expert Opinion on Emerging Drugs
|January 16, 2010
Summary
New anticoagulant (AC) drugs offer improved efficacy and safety for preventing and treating venous thromboembolism (VTE). Further post-marketing studies are needed to address remaining concerns for optimal patient care.
Area of Science:
- Pharmacology
- Thrombosis Research
- Clinical Trials
Background:
- Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a significant health concern.
- Anticoagulant (AC) drugs are crucial for VTE management but have limitations, driving the development of novel agents.
Purpose of the Study:
- To review and compare the advantages and disadvantages of emerging ACs against currently available treatments.
- To assess the efficacy and safety of new ACs for VTE prevention and treatment.
Main Methods:
- Systematic review of Phase III clinical trial results for new ACs.
- Analysis of studies published between 2003 and September 2009.
- Comparison of emerging ACs with standard VTE therapies.
Main Results:
- Emerging ACs demonstrate promising efficacy and safety profiles for VTE prophylaxis, particularly post-orthopaedic surgery.
- The review provides insights into the potential use of new ACs for VTE treatment.
- Comparative data highlights the benefits and drawbacks of novel anticoagulants versus established treatments.
Conclusions:
- Novel anticoagulants represent a significant advancement in VTE management, offering easier, effective, and safer prophylactic and therapeutic options.
- Careful consideration and post-marketing surveillance are essential to address remaining uncertainties regarding the use of these new ACs.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...